After treatment with doxorubicin at the IC50, the MAP1B mRNA level in BC cells was significantly decreased (Figure 7C,D), and the ABL2 mRNA level was significantly increased (Figure 7E,F). This evidence concerns the gene ABL2 and breast cancer.